ClinicalTrials.gg
CompletedNCT02223260Updated Sep 20, 2016Results posted

Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age

A Phase 2 interventional study of dabigatran in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Completed at 4 sites in 3 countries. Open to participants aged Up to 12 Months. Per ClinicalTrials.gov, last updated 2016-09-20.

Sponsored by Boehringer Ingelheim · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
Up to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.

Enrollment
16th of 17
8 · median 148
Started
2014
with 1 other
Phase 2
7 of 17
none open now
Registered
14th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 16th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 14th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: Up to 12 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing dabigatran in Venous Thromboembolism, or all of them as a file.
02

Study summary

The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm dabigatran etexilate dosing algorithm for children aged less than 1 year.

Read the detailed description

Purpose:

03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
Up to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates and infants with aged \< 12 months at Visit 1
  • Objective diagnosis of VTE
  • End of planned treatment course with anticoagulant therapy as per standard of care at the investigator site.
  • Written provided by the patient's parent(s) (or legal guardian) according to local regulations at Visit 1.

Exclusion criteria

Exclusion criteria:

  • Weight less than 3 kg at Visit 1
  • Conditions associated with an increased risk of bleeding
  • renal dysfunction
  • hepatic disease
  • Anemia or thrombocytopenia at screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    dabigatran

    open label arm with dabigatran oral liquid formulation as single dose

    Drug: dabigatran

Interventions

  • Experimental dose chosen based on age and weight

06

What researchers measure

Primary outcomes

  1. Plasma Concentrations of Total Dabigatran, 2h and 12 h (+/-2h) Post Administration of Dabigatran Etexilate

    Plasma concentrations of total dabigatran, 2h and 12 h (+/-2h) post administration of dabigatran etexilate.

    Time frame: 2 hours (h) and 12h after drug administration on day 1

  2. Central Measurement: The Mean aPTT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

    Central measurement: The mean activated partial thromboplastin time (aPTT) coagulation time at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.

    Time frame: 2 h, and 12 h after dosing on day 1

  3. Central Measurement: The Mean of ECT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

    Central measurement: The mean of Ecarin Clotting Time (ECT) coagulation time at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.

    Time frame: 2 h, and 12 h after dosing on day 1

  4. Central Measurement: The Mean of Diluted Thrombin Time (dTT) Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

    Central measurement: The mean of dTT (AntiFactor IIa activity) coagulation time at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.

    Time frame: 2 h, and 12 h after dosing on day 1

  5. Central Measurement: The Mean aPTT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

    Central measurement: The mean aPTT (activated partial thromboplastin time) ratio at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. aPTT ratio= aPTT (post dose)/aPTT (baseline). The mean of aPTT ratio is presented.

    Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1

  6. Central Measurement: The Mean ECT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

    Central measurement: The mean Ecarin Clotting Time (ECT) ratio at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. ECT ratio= ECT(Post dose)/ECT(baseline), The mean of ECT ratio is presented.

    Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1

  7. Central Measurement: The Mean of dTT Ratio at 2h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

    Central measurement: The mean of dTT (AntiFactor IIa activity) ratio at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. dTT ratio= dTT(post dose)/dTT(baseline). The mean of dTT ratio is presented.

    Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1

Secondary outcomes

  1. PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters APTT Values.

    Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters APTT values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.

    Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1

  2. PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters ECT Values.

    Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters ECT values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.

    Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1

  3. PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters dTT Values.

    Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters dTT (AntiFactor IIa activity) values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.

    Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1

  4. Incidence of All Bleeding Events (Major, CRNM and Minor) During the Treatment Period.

    Percentage of patients with Incidence of all bleeding events(major, clinically relevant non-major (CRNM) \& minor) during the treatment period (including the residual effect period).Bleeding events were classified as follow: Major bleeding: 1) Fatal bleeding 2) Clinically overt bleeding associated with decrease in haemoglobin of at least 2 g/dL (20 g/L) in 24-h-period 3) Bleeding that was retroperitoneal, pulmonary, intracranial, or otherwise involved the central nervous system 4) Bleeding that required surgical intervention in an operating suite. CRNM bleeding: 1) Overt bleeding for which a blood product was administered \& which was not directly attributable to the patient's underlying medical condition 2) Bleeding that required medical or surgical intervention to restore haemostasis, other than in an operating suite. Minor bleeding defined as any overt or macroscopic evidence of bleeding that did not fulfil the criteria for either major bleeding or CRNM bleeding.

    Time frame: Within two days after the administration of trial medication, up to 3 days

  5. Incidence of All AEs During the Treatment Period

    Percentage of patients with all adverse events (AEs) during the treatment period (including REP).

    Time frame: Within two days after the administration of trial medication, up to 3 days

  6. Global Assessment of Acceptability and Tolerability of Study Medication

    The investigator was to provide a global clinical assessment of tolerability and acceptability of study medication by the patient.This assessment was based on 5-point scale (good, satisfactory, not satisfactory, bad, not assessable).

    Time frame: Day 1 (immediately after dosing)

07

Results

Posted Sep 20, 2016

Participant flow

Participant flow — Overall Study
MilestoneDabigatran Etexilate
Started8
Completed8
Not completed0

Outcome measures

PrimaryPlasma Concentrations of Total Dabigatran, 2h and 12 h (+/-2h) Post Administration of Dabigatran Etexilate

Plasma concentrations of total dabigatran, 2h and 12 h (+/-2h) post administration of dabigatran etexilate.

Time frame:
2 hours (h) and 12h after drug administration on day 1
Reported as:
Geometric mean · ng/mL
Plasma Concentrations of Total Dabigatran, 2h and 12 h (+/-2h) Post Administration of Dabigatran Etexilate
ng/mLDabigatran Etexilate
2h120.0 ± 62.1
12h60.4 ± 30.0
PrimaryCentral Measurement: The Mean aPTT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

Central measurement: The mean activated partial thromboplastin time (aPTT) coagulation time at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.

Time frame:
2 h, and 12 h after dosing on day 1
Reported as:
Mean · second
Central Measurement: The Mean aPTT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
secondDabigatran Etexilate
E278.9 ± 26.7
E1262.8 ± 27.7
PrimaryCentral Measurement: The Mean of ECT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

Central measurement: The mean of Ecarin Clotting Time (ECT) coagulation time at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.

Time frame:
2 h, and 12 h after dosing on day 1
Reported as:
Mean · second
Central Measurement: The Mean of ECT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
secondDabigatran Etexilate
E2101 ± 44.3
E1266.9 ± 23.5
PrimaryCentral Measurement: The Mean of Diluted Thrombin Time (dTT) Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

Central measurement: The mean of dTT (AntiFactor IIa activity) coagulation time at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.

Time frame:
2 h, and 12 h after dosing on day 1
Reported as:
Mean · second
Central Measurement: The Mean of Diluted Thrombin Time (dTT) Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
secondDabigatran Etexilate
E248.7 ± 24
E1238.6 ± 8.12
PrimaryCentral Measurement: The Mean aPTT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

Central measurement: The mean aPTT (activated partial thromboplastin time) ratio at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. aPTT ratio= aPTT (post dose)/aPTT (baseline). The mean of aPTT ratio is presented.

Time frame:
baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Reported as:
Mean · ratio
Central Measurement: The Mean aPTT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
ratioDabigatran Etexilate
ER21.86 ± 19.5
ER121.47 ± 17.7
PrimaryCentral Measurement: The Mean ECT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

Central measurement: The mean Ecarin Clotting Time (ECT) ratio at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. ECT ratio= ECT(Post dose)/ECT(baseline), The mean of ECT ratio is presented.

Time frame:
baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Reported as:
Mean · Ratio
Central Measurement: The Mean ECT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
RatioDabigatran Etexilate
ER22.42 ± 34.2
ER121.63 ± 13.8
PrimaryCentral Measurement: The Mean of dTT Ratio at 2h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.

Central measurement: The mean of dTT (AntiFactor IIa activity) ratio at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. dTT ratio= dTT(post dose)/dTT(baseline). The mean of dTT ratio is presented.

Time frame:
baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Reported as:
Mean · ratio
Central Measurement: The Mean of dTT Ratio at 2h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
ratioDabigatran Etexilate
ER21.59 ± 25.4
ER121.26 ± 5.67
SecondaryPK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters APTT Values.

Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters APTT values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.

Time frame:
baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Reported as:
Number · R-Square
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters APTT Values.
R-SquareDabigatran Etexilate
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters APTT Values.0.752
SecondaryPK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters ECT Values.

Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters ECT values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.

Time frame:
baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Reported as:
Number · R-Square
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters ECT Values.
R-SquareDabigatran Etexilate
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters ECT Values.0.858
SecondaryPK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters dTT Values.

Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters dTT (AntiFactor IIa activity) values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.

Time frame:
baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Reported as:
Number · R-Square
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters dTT Values.
R-SquareDabigatran Etexilate
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters dTT Values.0.920
SecondaryIncidence of All Bleeding Events (Major, CRNM and Minor) During the Treatment Period.

Percentage of patients with Incidence of all bleeding events(major, clinically relevant non-major (CRNM) \& minor) during the treatment period (including the residual effect period).Bleeding events were classified as follow: Major bleeding: 1) Fatal bleeding 2) Clinically overt bleeding associated with decrease in haemoglobin of at least 2 g/dL (20 g/L) in 24-h-period 3) Bleeding that was retroperitoneal, pulmonary, intracranial, or otherwise involved the central nervous system 4) Bleeding that required surgical intervention in an operating suite. CRNM bleeding: 1) Overt bleeding for which a blood product was administered \& which was not directly attributable to the patient's underlying medical condition 2) Bleeding that required medical or surgical intervention to restore haemostasis, other than in an operating suite. Minor bleeding defined as any overt or macroscopic evidence of bleeding that did not fulfil the criteria for either major bleeding or CRNM bleeding.

Time frame:
Within two days after the administration of trial medication, up to 3 days
Reported as:
Number · Percentage of participants
Incidence of All Bleeding Events (Major, CRNM and Minor) During the Treatment Period.
Percentage of participantsDabigatran Etexilate
Incidence of All Bleeding Events (Major, CRNM and Minor) During the Treatment Period.0.0
SecondaryIncidence of All AEs During the Treatment Period

Percentage of patients with all adverse events (AEs) during the treatment period (including REP).

Time frame:
Within two days after the administration of trial medication, up to 3 days
Reported as:
Number · percentage of participants
Incidence of All AEs During the Treatment Period
percentage of participantsDabigatran Etexilate
Incidence of All AEs During the Treatment Period0.0
SecondaryGlobal Assessment of Acceptability and Tolerability of Study Medication

The investigator was to provide a global clinical assessment of tolerability and acceptability of study medication by the patient.This assessment was based on 5-point scale (good, satisfactory, not satisfactory, bad, not assessable).

Time frame:
Day 1 (immediately after dosing)
Reported as:
Number · percentage of participants
Global Assessment of Acceptability and Tolerability of Study Medication
percentage of participantsDabigatran Etexilate
Good75.0
Satisfactory12.5
Not satisfactory0.0
Bad12.5
Not assessable0.0

Adverse events

Collected over Within two days after the administration of trial medication, up to 3 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate—0/8 (0%)0/8 (0%)

Baseline characteristics

Treated set (TS): the treated set included 8 patients who were dispensed study medication and were documented to have taken at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(Months)Dabigatran Etexilate
Mean2.912 ± 1.694
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran Etexilate
Female5
Male3
08

Study locations

4 sites
  • 1160.105.10002 Boehringer Ingelheim Investigational Site
    Ottawa, Ontario, Canada
  • 1160.105.10003 Boehringer Ingelheim Investigational Site
    Montreal, Quebec, Canada
  • 1160.105.33001 Boehringer Ingelheim Investigational Site
    Paris, France
  • 1160.105.70005 Boehringer Ingelheim Investigational Site
    Kazan, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Jan 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2014
First posted
Aug 22, 2014
Start
Sep 2014
Primary completionActual
Jan 2016
CompletionActual
Feb 2016
Results first posted
Sep 20, 2016
Last update
Sep 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02223260
Responsible party
Sponsor
First posted
Aug 22, 2014
Start date
Sep 2014
Primary completion
Jan 2016
Completion
Feb 2016
Results posted
Sep 20, 2016
Last update
Sep 20, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion